

Subject: Medical Science Liaison (MSL) Notes - Introduction of CardioRelief

Date: December 10, 2025

Provider: Dr. Elizabeth Hayes

Title: Cardiologist

Institution: HeartWell Cardiovascular Clinic

Summary of Key Discussion Points:

1. Introduction:

- Introduced CardioRelief as an innovative therapy for managing hypertension and reducing cardiovascular risk.
- Emphasized its unique mechanism targeting both blood pressure regulation and vascular health.

2. Provider's Current Patient Cases:

- Dr. Hayes expressed interest in advanced treatments for hypertension, particularly in patients with comorbidities.
- Discussed specific cases where current antihypertensive medications have shown limitations or tolerability issues.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing CardioRelief's ability to effectively lower blood pressure and improve vascular function.
- Highlighted statistically significant reductions in both systolic and diastolic blood pressure measurements.

4. Safety Profile:

- Discussed the favorable safety profile of CardioRelief, with minimal reported adverse effects.
- Dr. Hayes inquired about potential interactions with commonly prescribed cardiovascular medications and the long-term safety considerations.

5. Mechanism of Action:

- Provided a detailed explanation of CardioRelief's mechanism, focusing on its dual-action approach in modulating blood pressure and supporting arterial health.
- Dr. Hayes appreciated the detailed explanation and sought insights into potential benefits for patients with resistant hypertension.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through a once-daily oral tablet.
- Shared patient education materials emphasizing the importance of consistent blood pressure management and lifestyle improvements.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on CardioRelief's potential in preventing cardiovascular events and addressing specific risk factors.
- Discussed plans for exploring combination therapies to address diverse cardiovascular conditions often present in hypertensive patients.

8. Competitive Landscape:

- Compared CardioRelief to existing antihypertensive medications, emphasizing its unique dual-action mechanism and potential for comprehensive cardiovascular risk reduction.
- Discussed the need for personalized treatment plans considering the various cardiovascular risk profiles of patients.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for cardiology clinics.
- Discussed potential affordability concerns and patient assistance programs for individuals seeking advanced cardiovascular care.

10. Action Items and Follow-Up:

- Dr. Hayes expressed keen interest in incorporating CardioRelief into her practice for patients with resistant hypertension.
- Agreed upon a follow-up in three months to assess patient response and discuss any emerging concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Hayes's commitment to advancing cardiovascular care.
- Reiterated commitment to ongoing collaboration and support for the HeartWell Cardiovascular Clinic.